Fraxinellone
Based on 4 publication(s) in Google Scholar
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.91%
- No. CAS: 28808-62-0
- Fòrmula: C14H16O3
- Peso molecular:232.28
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-N0037
AlbiflorinNeuroprotective Agent -
HY-19991
BMS-1PD-1/PD-L1 PPI Inhibitor -
HY-32736
TriptonideWnt Signaling Inhibitor -
HY-N0669
Steviosidesweetener -
HY-N0494
GentiopicrosideCytochrome P450 Inhibitor -
HY-N0285
ImperatorinCholinesterase (ChE) Inhibitor -
HY-N0596
PanaxadiolHIF-1α/STAT3 Inhibitor -
HY-N0242R
Fraxinellone (Standard)STAT Inhibitor -
HY-19745
BMS-202 -
HY-101093
CA-170VISTA/PD-L1 Inhibitor -
HY-N0892
AKBANrf2 Activator -
HY-138407
EvixapodlinPD-1/PD-L1 PPI Inhibitor
Publications Citing Use of MedChemExpress (MCE) Fraxinellone
More
Customer Validation & Images
-
RT-PCR
-
WB
-
Cell Proliferation/Viability Assay
-
IHC
-
IF
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CAL-27 | IC50 |
22.4 μg/mL
Compound: Frax
|
Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 34463097] |
| SCC-9 | IC50 |
43.4 μg/mL
Compound: Frax
|
Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 34463097] |
In Vitro
Fraxinellone (0-100 μM；12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells
-
Concentration:0 μM, 10 μM, 30 μM, 100 μM
-
Incubation Time:12 hours
-
Result:Inhibited the percent of PD-L1 positive cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:30 and 100 mg/kg
-
Administration:Oral gavage; 30 and 100 mg/kg; every three days; 30 days
-
Result:Significantly suppressed tumor growth.
Chemical Information
-
No. CAS 28808-62-0
-
Appearance Solid
-
Peso molecular 232.28
-
Fòrmula C14H16O3
-
Color White to off-white
-
SMILES
O=C1O[C@@H](C2=COC=C2)[C@]3(C)CCCC(C)=C31
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Fraxinellone alleviates colitis-related intestinal fibrosis by blocking the circuit between PD-1+ Th17 cells and fibroblasts. [Abstract]2024 Jun 30:135:112298. PMID: 38776854 -
Int J Biochem Cell Biol
Inhibition of ERO1A by TCF21 curbs aerobic glycolysis and enhances immune recognition in lung adenocarcinoma. [Abstract]2025 Oct:187:106831. PMID: 40659157 -
Biomed Pharmacother
Fraxinellone protects against cardiac injury and decreases ventricular fibrillation susceptibility during myocardial ischemia-reperfusion. [Abstract]2024 Nov:180:117560. PMID: 39442236
Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]
mRNA content of IL6, TNFα and IL1β treated with Fraxinellone (FRA) (5 mg/kg, i.p.).
Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]
Western blot analysis of Bax and BCL2 treated with Fraxinellone (FRA) (5 mg/kg, i.p.)
Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]
Cell viability was measured by CCK8 treated with Fraxinellone (FRA) (20, 40, 80, 160 μM).
Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]
The typical representative of TH and GAP43 immunohistochemical staining in myocardial tissue treated with Fraxinellone (FRA) (5 mg/kg, i.p.).
Fraxinellone purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2024 Nov:180:117560. [Abstract]
The representative images of Cx43 immunofluorescence staining in myocardial tissue treated with Fraxinellone (FRA) (5 mg/kg, i.p.).
-
Biomed Pharmacother
Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway. [Abstract]2022 Sep:153:113416. PMID: 36076484
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (430.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3051 mL | 21.5257 mL | 43.0515 mL | 107.6287 mL |
| 5 mM | 0.8610 mL | 4.3051 mL | 8.6103 mL | 21.5257 mL | |
| 10 mM | 0.4305 mL | 2.1526 mL | 4.3051 mL | 10.7629 mL | |
| 15 mM | 0.2870 mL | 1.4350 mL | 2.8701 mL | 7.1752 mL | |
| 20 mM | 0.2153 mL | 1.0763 mL | 2.1526 mL | 5.3814 mL | |
| 25 mM | 0.1722 mL | 0.8610 mL | 1.7221 mL | 4.3051 mL | |
| 30 mM | 0.1435 mL | 0.7175 mL | 1.4350 mL | 3.5876 mL | |
| 40 mM | 0.1076 mL | 0.5381 mL | 1.0763 mL | 2.6907 mL | |
| 50 mM | 0.0861 mL | 0.4305 mL | 0.8610 mL | 2.1526 mL | |
| 60 mM | 0.0718 mL | 0.3588 mL | 0.7175 mL | 1.7938 mL | |
| 80 mM | 0.0538 mL | 0.2691 mL | 0.5381 mL | 1.3454 mL | |
| 100 mM | 0.0431 mL | 0.2153 mL | 0.4305 mL | 1.0763 mL |
Fraxinellone Related Classifications
HY-N0242 Related Classifications
Powered by Bioz